Fax: (011) 82-31-920-1520
A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum-based chemotherapy
Article first published online: 6 JUL 2006
Copyright © 2006 American Cancer Society
Volume 107, Issue 4, pages 799–805, 15 August 2006
How to Cite
Kim, H. T., Han, J.-Y., Lee, D. H., Chun, J. H., Lee, H. G., Lee, J. J., Kim, H. Y., Lee, S. Y. and Lee, J. S. (2006), A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum-based chemotherapy. Cancer, 107: 799–805. doi: 10.1002/cncr.22063
- Issue published online: 10 AUG 2006
- Article first published online: 6 JUL 2006
- Manuscript Accepted: 17 APR 2006
- Manuscript Revised: 16 APR 2006
- Manuscript Received: 18 NOV 2005
- NCC. Grant Number: 0210240
- non-small-cell lung cancer
Irinotecan (I) and cisplatin (P) are active chemotherapy agents with clinical synergy in non–small-cell lung cancer (NSCLC). We evaluated the efficacy of IP regimen as a salvage treatment of patients with NSCLC that progressed after nonplatinum-containing regimen(s).
Eligibility required histologically confirmed NSCLC, bidimensionally measurable disease, ECOG PS 0-2, and progressive disease after nonplatinum-based chemotherapy. Treatment consisted of I (65 mg/m2) and P (30 mg/m2) i.v. on Days 1 and 8 of a 21-day cycle, for a maximum of 6 cycles. An informed consent was obtained from all patients.
Between August 2002 and May 2004, 32 patients with median age of 56 years (range, 42–74) were enrolled. Twenty-four (75%) patients were men, and 28 (88%) had ECOG PS 0 or 1. Twenty-five patients had adenocarcinoma and 6 had squamous-cell carcinoma. All patients were evaluated for response and toxicity, and the response rate was 40.6%. After a median follow-up of 18.5 months, the median survival time was found to be 9.3 months, with a 1-year survival rate of 43.8%. Toxicities were moderate and manageable, with 47% G3 and 9% G4 neutropenia, 19% G3 diarrhea, and 22% G3 asthenia. There was no G4 nonhematologic toxicity.
The irinotecan and cisplatin combination is an active and well-tolerated regimen for the patients with advanced NSCLC that progressed after nonplatinum-containing regimen(s). Cancer 2006. © 2006 American Cancer Society.